Next Article in Journal
The Systematic Review of Artificial Intelligence Applications in Breast Cancer Diagnosis
Previous Article in Journal
The Role of Thromboprophylaxis in Patients with Portal Vein Thrombosis: A Life-Threatening Complication after Laparoscopic Sleeve Gastrectomy Following 8 Years of Experience in a Bariatric Center of Excellence
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 1
10.3390/diagnostics13010044
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Association between Diabetes Mellitus, High Monocyte/Lymphocyte Ratio, and Survival in Endometrial Cancer: A Retrospective Cohort Study

by
Ruo-Shi Bing
1,
Wing Lam Tsui
2 and
Dah-Ching Ding
2,3,*
1
Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Foundation, New Taipei City 23106, Taiwan
2
Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, Tzu Chi University, Hualien 970, Taiwan
3
Institute of Medical Sciences, College of Medicine, Tzu Chi University, Hualien 970, Taiwan
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(1), 44; https://doi.org/10.3390/diagnostics13010044
Submission received: 23 November 2022 / Revised: 20 December 2022 / Accepted: 21 December 2022 / Published: 23 December 2022
(This article belongs to the Section Clinical Laboratory Medicine)
Browse Figures
Review Reports Versions Notes

Abstract

:
This retrospective cohort study aimed to evaluate the factors related to endometrial cancer (EC) prognosis and survival in eastern Taiwan. The study involved 48 patients diagnosed with EC who underwent hysterectomy-based surgery at Hualien Tzu Chi hospital between January 2011 and June 2021. The patients’ medical history and laboratory examination results were reviewed. Progression-free survival and overall survival were determined. Categorical variables were analyzed using the chi-square test, and continuous variables were analyzed using the independent t-test. The receiver operating characteristic curve was used to predict diagnostic value. Factors associated with cancer mortality were identified via Cox regression analysis (p < 0.05). Patients were divided into the death (n = 7) and survival (n = 41) groups. The median age of the patients was 56 years (range: 31–71 years). The median observation period was 33.29 months. Diabetes mellitus (DM) and monocyte/lymphocyte ratio (MLR) > 0.23886 were significantly associated with cancer mortality (p = 0.024 and p = 0.028, respectively). MLR-low and MLR-high groups exhibited 5-year overall survival rates of 96% and 60%, respectively, and 5-year progression-free survival rates of 96% and 41%, respectively. DM and MLR of >0.2386 were suggested to be associated with cancer death, poor overall survival, and progression-free survival.

1. Introduction

Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, accounting for nearly 5% of the cancer cases [1]. In Taiwan, EC is ranked fifth in terms of female cancer incidence, with 2884 new cases in 2019. Elderly women with EC frequently present with postmenopausal vaginal bleeding. Therefore, the cancer is often diagnosed at an early stage [2]. Surgical treatments of EC include total hysterectomy with bilateral salpingo-oophorectomy and retroperitoneal lymphadenectomy [3]. Adjuvant therapy includes systemic chemotherapy and radiotherapy if advanced stages are noted [4].
Despite the early-stage detection of the disease, the 5-year overall survival (OS) of EC ranges from 74% to 91% [5]. However, the 5-year survival rate decreases to 57–66% or 20–26% for patients with stage III or IV of the disease, respectively, based on the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system [6]. Hence, it is important to identify the prognostic factors of EC to prevent premature death and improve overall patient outcome [7].
Numerous studies have identified the prognostic factors of EC, such as histological grading and type, myometrial invasion depth, lymphovascular invasion, lymph node status, age, serous and cervical involvement, tumor size, and stromal involvement [8]. Several biomarkers are also related to the prognosis of EC, such as TP53 mutations [9] and HF4 (human epididymis protein 4) [10]. A high monocyte/lymphocyte ratio (MLR) is associated with poor prognosis in several cancers, such as colorectal cancer [11], ovarian cancer [12], and lymphoma [13]. In the case of EC, studies have suggested that MLR is a solid independent prognostic predictive factor and could provide an additional value beyond serving as a traditional clinicopathological factor [14].
Apart from MLR, predisposing diabetes mellitus (DM), primarily type 2, may also affect the survival of patients with EC [15]. Many studies have suggested that the state of insulin resistance and subsequently, the state of hyperinsulinemia in patients increase the risk of endometrial carcinogenesis, ultimately leading to cancer development and lowering cancer survival [15]. Hence, our study aimed to evaluate the factors, including MLR and history of DM, related to endometrial cancer prognosis and survival in the eastern Taiwanese population.

2. Materials and Methods

2.1. Ethics

This study was approved by the Research Ethics Committee of Hualien Tzu Chi Hospital, Hualien, Taiwan (IRB 111-111-B). We retrospectively analyzed the data of all patients in our hospital who had EC (C54.1 of ICD-10-CM) and underwent hysterectomy-based surgical treatment between January 2011 and June 2021. The Research Ethics Committee of Hualien Tzu Chi Hospital waived the requirement for informed consent. This study was conducted in accordance with the Declaration of Helsinki. Relevant guidelines and regulations were implemented for all the methods.

2.2. Study Population

This retrospective study comprised 48 patients diagnosed with EC who underwent hysterectomy-based surgical treatment at our hospital between January 2011 and June 2021. Patients without full laboratory data, including complete blood count and differential count within two weeks before surgery, were excluded. Patients with active infections, autoimmune diseases, or hematological diseases were excluded from this study. EC diagnosis was confirmed by a pathologist.

2.3. Data Collection

In this study, we collected clinical information of the patients from the electronic medical records in the hospital information system. Patients who were diagnosed with malignant neoplasms of the endometrium (C54.1 ICD-10-CM) and who underwent hysterectomy-based surgery at our hospital were selected for the study. We collected information including (i) basic information such as age at surgery, body mass index (BMI), history of DM, and hypertension, as well as family history of gynecological cancer; (ii) pathological results including histological subtype, tumor grade, lymphovascular invasion (LVSI), lymph node (LN) invasion, clinical staging, FIGO staging, and immunohistochemistry stain of estrogen receptor (ER) and progesterone receptor (PR); (iii) laboratory data including complete blood count, absolute neutrophil count, absolute lymphocyte count, and absolute monocyte count; (iv) operation history, including surgery date, type, and route. Clinical and tumor grades were determined using the FIGO staging system. OS was defined as the time from the date of hysterectomy-based surgical treatment to the date of death or last follow-up. Progression-free survival (PFS) was defined as the time from the date of hysterectomy-based surgical treatment to the date of the first recurrence or last follow-up.

2.4. MLR, NLR and PLR Calculation

MLR was calculated by monocyte count divided by lymphocyte count. Neutrophil/lymphocyte ratio (NLR) was calculated by neutrophil count divided by lymphocyte count. Platelet/lymphocyte ratio (PLR) was calculated by platelet count divided by lymphocyte count.

2.5. Statistical Analysis

Categorical variables were analyzed using the chi-square test, and continuous variables were analyzed using the independent t-test. The receiver operating characteristic (ROC) curve was used to determine the largest area under the curve (AUC) to predict diagnostic value. Cox regression analysis was performed to investigate the factors associated with cancer mortality. All analyses were performed using SPSS 24.0 (IBM Corp., Armonk, NY, USA). Statistical significance was set at p < 0.05.

3. Results

3.1. Demographics

A total of 48 patients were ultimately eligible for the study and were divided into death (n = 7) and survival (n = 41) groups. The flowchart describing the patient selection process in the study is shown in Figure 1. All patients underwent hysterectomy-based surgery including bilateral salpingo-oophorectomy. The demographic characteristics of the patients are summarized in Table 1. The median age of the patients was 56 years (range: 31–71 years). The median observation period was 33.29 months. Demographic data including age, BMI, hypertension, stage, histology, tumor grade, ER, PR, LVSI, LN invasion, neutrophil/lymphocyte ratio (NLR, p = 0.085), and platelet/lymphocyte ratio (PLR, p = 0.725) were not significantly different between the two groups. However, the incidences of DM (p = 0.033) and MLR (p = 0.018) were significantly different between the two groups (Table 1). The median NLR, MLR, and PLR were 3.36 (range: 1–18), 0.23 (range: 0.1–0.9), and 176.67 (range: 59.21–697.25), respectively.

3.2. Cox Regression Analysis of the Factors Associated with Mortality

Table 2 lists the factors associated with EC-related mortality. DM and MLR > 0.23886 were significantly associated with cancer mortality (p = 0.024 and p = 0.028, respectively). In contrast, there was no significant association between cancer mortality and age, BMI, NLR, PLR, histology subtype, endometrial grade, ER, PR, LVSI, or lymph node invasion. Factors with a p-value < 0.1 were selected for adjustment in model 1. The analysis revealed that DM was associated with cancer mortality (p = 0.030). Due to the small number of patients with late FIGO stage in Adjusted Model 1, we further adjusted the factors in model 2. After adjustment in Model 2, an M/L ratio >0.2386 was associated with cancer mortality (p = 0.046).

3.3. ROC Curves of Various Ratios

ROC curves for the optimal cutoff values of NLR, MLR, and PLR are shown in Figure 2, Figure 3 and Figure 4. The cutoff value of NLR was 3.01 (AUC = 0.871). As for MLR and PLR, the cutoff value was 0.234 (AUC = 0.829) and 154.33 (AUC = 0.617), respectively.

3.4. Comparative Characteristics of High and Low NLR/MLR/PLR Groups

We further divided the patients into low and high NLR, MLR, and PLR groups based on the cutoff values (Table 3). The NLR was significantly associated with the incidence of DM (p = 0.008) and FIGO stage (p = 0.037). However, MLR was significantly associated with the FIGO stage (p = 0.002), histological subtype (p = 0.018), lymphovascular invasion (p = 0.015), and lymph node invasion (p = 0.035). There was no significant association between the PLR and clinicopathological factors.

3.5. OS and PFS

OS and PFS were evaluated using the Kaplan–Meier method, stratified by the MLR cutoff value (Figure 5 and Figure 6). A higher MLR was associated with a significantly worse OS (p = 0.006) and PFS (p = 0.004) than a lower MLR. The 5-year OS rates of MLR-low and MLR-high groups were 96% and 60%, respectively. The 5-year PFS rates of MLR-low and MLR-high groups were 96% and 41%, respectively.

4. Discussion

In this retrospective cohort study exploring the effects of MLR and DM on the survival of patients with EC, we found that the MLR was significantly different between the two groups of patients in terms of EC survival. The statistical analysis showed that an MLR of >0.2386 was associated with cancer-related death, worse OS, and worse PFS. DM was also associated with cancer-related deaths. In contrast, other risk factors such as age, BMI, stage, tumor grade, LVSI, and lymph node invasion were not associated with cancer-related death in this study. The MLR represents a delicate balance between the two blood cells (monocytes and lymphocytes) and is a novel indicator of inflammation [16]. Numerous studies have suggested that MLR is an independent and crucial prognostic factor for various diseases [17]. It provides valuable information regarding patients’ abnormal immune status against diseases [18].
In general, lymphocyte count is a useful indicator of host immunity [19]. It is crucial to the immune surveillance and defense system against cancer cells. The tumor microenvironment not only consists of cancerous cells but also all other types of inflammatory cells. CD8+ T cells eliminate tumor cells through the action of granzymes and perforins [20]. CD4+ T cells induce and regulate T cell-mediated cytotoxicity [21]. On the contrary, they also release various cytokines, such as INF-γ, after being activated by tumor antigens, preventing macrophages from migrating away from the tumor antigens, as well as TNF-ɑ, IL-4, and IL-5. Therefore, a high lymphocyte count is favorable for patients with cancer [22].
However, monocytes are released by the bone marrow and circulate in the blood [23]. Following recruitment to tumor tissues, they transform into macrophages, specifically M1 and more importantly, M2 macrophages, which are also known as tumor-associated macrophages [23]. M1 macrophages are known to exhibit antitumor activity. However, tumor-associated macrophages produce vast amounts of anti-inflammatory cytokines, angiogenic factors, and metalloproteases, which aid the growth of tumor cells [24]. Therefore, a high monocyte count is unfavorable for patients and imparts a negative effect on patient prognosis [22].
The results of our study were consistent with those of previous studies. Cong et al. found that a high MLR (>0.22) negatively affected the survival of endometrial cancer patients [25]. Song et al. showed similar results, in which the cutoff point of MLR was 0.19 and an MLR higher than that was associated with cancer recurrence and mortality [26]. Another study by Holub et al. reported an MLR cutoff of 0.18, with higher values leading to a poorer prognosis and a decrease in OS [27]. Leng et al. conducted a meta-analysis that included more than 5000 endometrial cancer patients and found that NLR or PLR was associated with OS and disease-free survival (DFS) and that NLR was associated with PFS only in univariate analysis but also that MLR was not associated with OS or DFS [28]. However, there were only two references included in the above study regarding MLR, and it found no correlation between MLR and OS or DFS. We thought the number of studies included in the meta-analysis was too small to drive a conclusion. Therefore, the current study could add to the current knowledge about the association between MLR and OS or DFS. There are still uncertainties regarding the cutoff point for MLR and its impact on the survival of EC, as each study had unique qualities in its study group. Nonetheless, there is no doubt that most recent studies unanimously point to the fact that a high MLR is an independent poor prognostic factor for EC.
A previous study by Luo et al. reported different results regarding diabetes and survival of patients with EC. In the study, although initial results showed that self-reported diabetes was negatively correlated to OS in EC, the significant relationship between diabetes and EC survival was no longer present after adjusting for BMI, treatment, medication, and duration of disease [29]. This indicates that the relationship between diabetes and EC involves various confounding factors that were not analyzed in our study, leading to the results being different from ours. Metformin was reported to increase survival in women with EC [30]. In our study, all DM patients had type 2 DM and received pharmacotherapy. However, the oral hypoglycemic agents varied among the patients.
EC stage and grade are known to be related to prognosis and survival [14]. In fact, another study using the SEER database confirmed that the EC stage and grade were correlated with survival [31]. However, the correlation between EC stage, grade, and survival in our study was only a trend but did not reach a statistical significance. We speculate that this might be due to our study’s small number of deaths, particularly when cancer itself may not be the cause.
This retrospective cohort study collected information from a hospital database. The patients included in our study had detailed medical records and provided their complete profiles, characteristics, and laboratory data. Therefore, recall bias was not observed. This also provided us with the opportunity to explore multiple prognostic factors simultaneously. However, there are several limitations in this study that need to be addressed, specifically its relatively small sample size. It is also a retrospective cohort study, hence confounding bias may affect the final result. Nevertheless, the results of this study have shed light on the importance of MLR in evaluating patient prognosis and mortality in EC. Large-scale studies should be conducted to further evaluate the accuracy and importance of MLR as well as its role in predicting the prognosis of patients with EC.

5. Conclusions

We demonstrated that an MLR of more than 0.2386 was suggested to be associated with cancer death, worse OS, and worse PFS compared to MLR under 0.2386. DM was also found to be associated with cancer-related deaths. Further large-scale trials are needed to corroborate the findings in this study.

Author Contributions

Conceptualization, D.-C.D. and R.-S.B.; methodology, R.-S.B.; investigation, R.-S.B.; resources, D.-C.D.; data curation, R.-S.B.; writing—original draft preparation, R.-S.B., W.L.T. and D.-C.D.; writing—review and editing, D.-C.D.; funding acquisition, R.-S.B. and D.-C.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Buddhist Tzu Chi Medical Foundation (grant number: TCMF-P 111-01).

Institutional Review Board Statement

This study was approved by the Research Ethics Committee of Hualien Tzu Chi Hospital (IRB 111-111-B; 23 May 2022).

Informed Consent Statement

Patient consent was waived due to low risk of patient safety.

Data Availability Statement

Not applicable.

Acknowledgments

We thank Wang, Jeng-Hung for statistical analysis assistance.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Clarke, M.A.; Long, B.J.; Del Mar Morillo, A.; Arbyn, M.; Bakkum-Gamez, J.N.; Wentzensen, N. Association of endometrial cancer risk with postmenopausal bleeding in women: A systematic review and meta-analysis. JAMA Intern. Med. 2018, 178, 1210–1222. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N.; Darai, E. Endometrial cancer. Lancet 2016, 387, 1094–1108. [Google Scholar] [CrossRef] [PubMed]
  3. Sonoda, Y. Surgical treatment for apparent early stage endometrial cancer. Obstet. Gynecol. Sci. 2014, 57, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Bestvina, C.M.; Fleming, G.F. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. Oncologist 2016, 21, 1250–1259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Lorusso, V.; Vallarelli, S.; Giotta, F. Adjuvant therapy of endometrial cancer: “Taxane or not taxane, this is the question”. Transl. Cancer Res. 2019, 8, 2220–2222. [Google Scholar] [CrossRef] [PubMed]
  6. Yoriki, K.; Mori, T.; Kokabu, T.; Matsushima, H.; Umemura, S.; Tarumi, Y.; Kitawaki, J. Estrogen-related receptor alpha induces epithelial-mesenchymal transition through cancer-stromal interactions in endometrial cancer. Sci. Rep. 2019, 9, 6697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Kasius, J.C.; Pijnenborg, J.M.A.; Lindemann, K.; Forsse, D.; van Zwol, J.; Kristensen, G.B.; Krakstad, C.; Werner, H.M.J.; Amant, F. Risk stratification of endometrial cancer patients: FIGO stage, biomarkers and molecular classification. Cancers 2021, 13, 5848. [Google Scholar] [CrossRef]
  8. Sabater, S.; Andres, I.; Lopez-Honrubia, V.; Marti-Laosa, M.M.; Castro-Larefors, S.; Berenguer, R.; Jimenez-Jimenez, E.; Sevillano, M.; Rovirosa, A.; Arenas, M. Does postoperative irradiation improve survival in early-stage endometrial cancer? Brachytherapy 2018, 17, 912–921. [Google Scholar] [CrossRef]
  9. Chen, Y.; Zhao, W.; Bi, F.; Pan, X.; Yin, L.; Zhao, C. Significance of TP53 mutational status-associated signature in the progression and prognosis of endometrial carcinoma. Oxid. Med. Cell. Longev. 2022, 2022, 1817339. [Google Scholar] [CrossRef]
  10. Han, L.N.; Han, Y.W.; Yan, P. Prognostic values of human epididymis Protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis. J. Obstet. Gynaecol. Res. 2022, 48, 2255–2269. [Google Scholar] [CrossRef]
  11. Jakubowska, K.; Koda, M.; Grudzińska, M.; Kańczuga-Koda, L.; Famulski, W. Monocyte-to-lymphocyte ratio as a prognostic factor in peripheral whole blood samples of colorectal cancer patients. World J. Gastroenterol. 2020, 26, 4639–4655. [Google Scholar] [CrossRef] [PubMed]
  12. Gong, J.; Jiang, H.; Shu, C.; Hu, M.Q.; Huang, Y.; Liu, Q.; Li, R.F. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: A meta-analysis. J. Ovarian Res. 2019, 12, 51. [Google Scholar] [CrossRef] [PubMed]
  13. Gao, F.; Hu, J.; Zhang, J.; Xu, Y. Prognostic value of peripheral blood lymphocyte/monocyte ratio in lymphoma. J. Cancer 2021, 12, 3407–3417. [Google Scholar] [CrossRef] [PubMed]
  14. Eo, W.K.; Kwon, S.; Koh, S.B.; Kim, M.J.; Ji, Y.I.; Lee, J.Y.; Suh, D.S.; Kim, K.H.; Kim, H.Y. The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of endometrial cancer. J. Cancer 2016, 7, 538–545. [Google Scholar] [CrossRef] [Green Version]
  15. Njoku, K.; Agnew, H.J.; Crosbie, E.J. Impact of type 2 diabetes mellitus on endometrial cancer survival: A prospective database analysis. Front. Oncol. 2022, 12, 899262. [Google Scholar] [CrossRef]
  16. Gawiński, C.; Michalski, W.; Mróz, A.; Wyrwicz, L. Correlation between lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and tumor-infiltrating lymphocytes (TILs) in left-sided colorectal cancer patients. Biology 2022, 11, 385. [Google Scholar] [CrossRef]
  17. Cheng, H.R.; Song, J.Y.; Zhang, Y.N.; Chen, Y.B.; Lin, G.Q.; Huang, G.Q.; He, J.C.; Wang, Z. High monocyte-to-lymphocyte ratio is associated with stroke-associated pneumonia. Front. Neurol. 2020, 11, 575809. [Google Scholar] [CrossRef]
  18. Stotz, M.; Szkandera, J.; Stojakovic, T.; Seidel, J.; Samonigg, H.; Kornprat, P.; Schaberl-Moser, R.; Seggewies, F.; Hoefler, G.; Gerger, A.; et al. The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Clin. Chem. Lab. Med. 2015, 53, 499–506. [Google Scholar] [CrossRef]
  19. Huang, H.; Li, L.; Luo, W.; Yang, Y.; Ni, Y.; Song, T.; Zhu, Y.; Yang, Y.; Zhang, L. Lymphocyte percentage as a valuable predictor of prognosis in lung cancer. J. Cell. Mol. Med. 2022, 26, 1918–1931. [Google Scholar] [CrossRef]
  20. Tsukumo, S.I.; Yasutomo, K. Regulation of CD8+ T cells and antitumor immunity by Notch signaling. Front. Immunol. 2018, 9, 101. [Google Scholar] [CrossRef]
  21. Takeuchi, A.; Saito, T. CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function. Front. Immunol. 2017, 8, 194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Coico, R. Immunology: A Short Course; John Wiley & Sons: Hoboken, NJ, USA, 2021; ISBN 9781119551577. [Google Scholar]
  23. Geissmann, F.; Manz, M.G.; Jung, S.; Sieweke, M.H.; Merad, M.; Ley, K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327, 656–661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Yang, Q.; Guo, N.; Zhou, Y.; Chen, J.; Wei, Q.; Han, M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm. Sin. B 2020, 10, 2156–2170. [Google Scholar] [CrossRef] [PubMed]
  25. Cong, R.; Kong, F.; Ma, J.; Li, Q.; Wu, Q.; Ma, X. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: A superior prognostic factor of endometrial cancer. BMC Cancer 2020, 20, 464. [Google Scholar] [CrossRef] [PubMed]
  26. Song, H.; Jeong, M.J.; Cha, J.; Lee, J.S.; Yoo, J.G.; Song, M.J.; Kim, J.H.; Lee, S.J.; Lee, H.N.; Yoon, J.H.; et al. Preoperative neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio as a prognostic factor in non-endometrioid endometrial cancer. Int. J. Med. Sci. 2021, 18, 3712–3717. [Google Scholar] [CrossRef] [PubMed]
  27. Holub, K.; Busato, F.; Gouy, S.; Sun, R.; Pautier, P.; Genestie, C.; Morice, P.; Leary, A.; Deutsch, E.; Haie-Meder, C.; et al. Analysis of systemic inflammatory factors and survival outcomes in endometrial cancer patients staged I-III FIGO and treated with postoperative external radiotherapy. J. Clin. Med. 2020, 9, 1441. [Google Scholar] [CrossRef]
  28. Leng, J.; Wu, F.; Zhang, L. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, or monocyte-to-lymphocyte ratio in endometrial neoplasms: A systematic review and meta-analysis. Front. Oncol. 2022, 12, 734948. [Google Scholar] [CrossRef]
  29. Luo, J.; Beresford, S.; Chen, C.; Chlebowski, R.; Garcia, L.; Kuller, L.; Regier, M.; Wactawski-Wende, J.; Margolis, K.L. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br. J. Cancer 2014, 111, 1432–1439. [Google Scholar] [CrossRef] [Green Version]
  30. Chu, D.; Wu, J.; Wang, K.; Zhao, M.; Wang, C.; Li, L.; Guo, R. Effect of Metformin Use on the Risk and Prognosis of Endometrial Cancer: A Systematic Review and Meta-Analysis. BMC Cancer 2018, 18, 438. [Google Scholar] [CrossRef] [Green Version]
  31. Zhu, L.; Sun, X.; Bai, W. Nomograms for predicting cancer-specific and overall survival among patients with endometrial carcinoma: A SEER based study. Front. Oncol. 2020, 10, 269. [Google Scholar] [CrossRef]
Diagnostics 13 00044 g001 550
Figure 1. Flowchart describing the patient selection for the study. EC: endometrial cancer.
Figure 1. Flowchart describing the patient selection for the study. EC: endometrial cancer.
Diagnostics 13 00044 g001
Diagnostics 13 00044 g002 550
Figure 2. The receiver operating characteristic (ROC) curve of the neutrophil/lymphocyte ratio predicts cancer death (area under the curve [AUC] = 0.871).
Figure 2. The receiver operating characteristic (ROC) curve of the neutrophil/lymphocyte ratio predicts cancer death (area under the curve [AUC] = 0.871).
Diagnostics 13 00044 g002
Diagnostics 13 00044 g003 550
Figure 3. The receiver operating characteristic (ROC) curve of the monocyte/lymphocyte ratio predicts cancer death (area under the curve [AUC] = 0.829).
Figure 3. The receiver operating characteristic (ROC) curve of the monocyte/lymphocyte ratio predicts cancer death (area under the curve [AUC] = 0.829).
Diagnostics 13 00044 g003
Diagnostics 13 00044 g004 550
Figure 4. The receiver operating characteristic (ROC) curve of the platelet/lymphocyte ratio predicts cancer death (area under the curve [AUC] = 0.617).
Figure 4. The receiver operating characteristic (ROC) curve of the platelet/lymphocyte ratio predicts cancer death (area under the curve [AUC] = 0.617).
Diagnostics 13 00044 g004
Diagnostics 13 00044 g005 550
Figure 5. Overall survival stratified by high and low monocyte/lymphocyte ratio (MLR) (5-year survival rate = 96% and 60% in the MLR-low and MLR-high groups, respectively).
Figure 5. Overall survival stratified by high and low monocyte/lymphocyte ratio (MLR) (5-year survival rate = 96% and 60% in the MLR-low and MLR-high groups, respectively).
Diagnostics 13 00044 g005
Diagnostics 13 00044 g006 550
Figure 6. Progression-free survival stratified by high and low monocyte/lymphocyte ratio (MLR) (5-year progress-free survival rate = 96% and 41% in the MLR-low and MLR-high groups, respectively).
Figure 6. Progression-free survival stratified by high and low monocyte/lymphocyte ratio (MLR) (5-year progress-free survival rate = 96% and 41% in the MLR-low and MLR-high groups, respectively).
Diagnostics 13 00044 g006
Table
Table 1. Demographic characteristics of patient data involved in the study (n = 48).
Table 1. Demographic characteristics of patient data involved in the study (n = 48).
DeathTotalp-Value
NoYes
N41748
Age55.95 ± 8.8361.57 ± 7.3256.77 ± 8.790.119
BMI28.38 ± 5.1330.97 ± 4.3028.76 ± 5.060.215
DM (%)11 (26.8%)5 (71.4%)16 (33.3%)0.033 *
Hypertension (%)23 (56.1%)4 (57.1%)27 (56.3%)1.000
Stage (%)---0.288
128 (68.3%)3 (42.9%)31 (64.6%)
25 (12.2%)1 (14.3%)6 (12.5%)
35 (12.2%)2 (28.6%)7 (14.6%)
43 (7.3%)1 (14.3%)4 (8.3%)
Histology subtype (%)---0.684
Mixed cell carcinoma4 (9.8%)1 (14.3%)5 (10.4%)
Endometrioid32 (78.0%)5 (71.4%)37 (77.0%)
Serous carcinoma4 (9.8%)1 (14.3%)5 (10.4%)
Clear cell carcinoma1 (2.4%)0 (0.0%)1 (2.1%)
Tumor grade (%) N = 48---0.875
121 (51.2%)4 (57.1%)25 (52.1%)
29 (22.0%)1 (14.3%)10 (20.8%)
311 (26.8%)2 (28.6%)13 (27.1%)
Immunohistochemistry
ER 0.363
06 (14.6%)2 (28.6%)8 (16.7%)
1+11 (26.8%)3 (42.9%)14 (29.2%)
2+11 (26.8%)0 (0.0%)11 (22.9%)
3+13 (31.7%)2 (28.6%)15 (31.1%)
PR N = 46 0.681
05 (13.8%)1 (14.3%)6 (13.0%)
1+8 (20.5%)3 (42.9%)11 (23.9%)
2+10 (25.6%)1 (14.3%)11 (23.9%)
3+14 (41.0%)2 (28.6%)18 (39.1%)
Lymphovascular invasion (%) N = 4719 (47.5%)5 (71.4%)24 (51.1%)0.416
LN invasion (%) N = 416 (17.1%)2 (33.3%)8 (19.5%)0.578
NLR3.04 ± 3.105.23 ± 2.683.36 ± 3.110.085
MLR0.21 ± 0.150.36 ± 0.150.23 ± 0.160.018 *
PLR174.14 ± 123.41191.47 ± 92.19176.67 ± 118.680.725
Data are presented as n or mean ± standard deviation; * p-value < 0.05 was considered statistically significant after the test; NLR: neutrophil/lymphocyte ratio, MLR: monocyte/lymphocyte ratio, PLR: platelet/lymphocyte ratio, LN: lymph node, BMI: body mass index, DM: diabetes mellitus, ER: estrogen receptor, PR: progesterone receptor. 0: no staining, 1+: weak staining, 2+: intermediate staining, 3+: strong staining.
Table
Table 2. Factors associated with mortality (n = 48).
Table 2. Factors associated with mortality (n = 48).
CrudeAdjusted (Model 1)Adjusted (Model 2)
HR (95% CI)p-ValueHR (95% CI)p-ValueHR (95% CI)p-Value
Age1.12 (0.99, 1.27)0.0731.02 (0.88, 1.19)0.7801.04 (0.90, 1.20)0.636
BMI1.12 (0.96, 1.30)0.145
DM (Yes vs. No)11.89 (1.39, 102.02)0.024 *21.54 (1.34, 344.93)0.030 *8.27 (0.81, 84.25)0.074
NLR > 3.0995274.63 (0.06, 1,236,601.52)0.191
MLR > 0.238610.87 (1.30, 90.83)0.028 *16.05 (0.9, 286.66)0.0598.88 (1.03, 76.28)0.046 *
PLR > 154.33093.34 (0.65, 17.24)0.150
Stage----
1ReferenceNAReferenceNA
20.99 (0.09, 10.88)0.99319.78 (0.66, 590.95)0.085
34.72 (0.75, 29.76)0.0982.16 (0.24, 19.29)0.489
43.66 (0.36, 36.82)0.2703.19 (0.25, 41.03)0.373
Histology--
Mixed cell carcinomaReferenceNA
Endometrioid0.43 (0.05, 3.86)0.451
Serous carcinoma0.85 (0.05, 13.68)0.910
Clear cell carcinoma0.00 (NA)0.991
Tumor grade--
1ReferenceNA
21.05 (0.19, 5.89)0.957
30.56 (0.06, 5.08)0.605
ER--
0ReferencesNA
1+0.43 (0.05, 3.86)0.451
2+0.85 (0.05, 13.86)0.910
3+0.85 (0.05, 13.68)0.991
PR N = 46--
0ReferencesNA
1+1.33 (0.14, 12.99)0.808
2+0.41 (0.03, 6.61)0.520
3+0.27 (0.02, 4.43)0.361
Lymphovascular invasion (Yes vs. No)1.52 (0.28, 8.43)0.630
LN invasion (Yes vs. No)3.23 (0.53, 19.52)0.202
Data are presented as hazard ratio (HR; 95% CI); * p-value < 0.05 was considered statistically significant after the test. Crude: age, DM, BMI, N/L, M/L, P/L, stage, histology, grade, lymphovascular invasion, LN invasion; Adjusted Model 1: age, DM, M/L > 0.2386, stage; Adjusted Model 2: age, DM, M/L > 0.2386; DM: diabetes mellitus, BMI: body mass index, NLR: neutrophil/lymphocyte ratio, MLR: monocyte/lymphocyte ratio, PLR: platelet/lymphocyte ratio, LN: lymph node, ER: estrogen receptor, PR: progesterone receptor. 0: no staining, 1+: weak staining, 2+: intermediate staining, 3+: strong staining.
Table
Table 3. Clinical and pathological characteristics of patients with EC in high and low NLR/MLR/PLR groups (n = 48).
Table 3. Clinical and pathological characteristics of patients with EC in high and low NLR/MLR/PLR groups (n = 48).
CharacteristicNLR-LowNLR-Highp-ValueMLR-LowMLR-Highp-ValuePLR-LowPLR-Highp-Value
N3315 3117 2820
Age55.39 ± 9.3959.80 ± 6.590.10855.61 ± 9.7558.88 ± 6.410.22155.57 ± 9.4758.45 ± 7.650.268
BMI28.61 ± 5.3829.09 ± 4.400.76728.16 ± 5.0329.85 ± 5.080.27129.14 ± 4.8728.23 ± 5.380.543
DM (%)7 (21.2%)9 (60.0%)0.008 *9 (29.0%)7 (41.2%)0.3938 (28.6%)8 (40.0%)0.408
Stage (%) 0.037 * 0.002 * 0.244
125 (75.8%)6 (40.0%) 24 (77.4%)7 (41.2%) 21 (75.0%)10 (50.0%)
24 (12.1%)2 (13.3%) 5 (16.1%)1 (5.9%) 3 (10.7%)3 (15.0%)
33 (9.1%)4 (26.7%) 2 (6.5%)5 (29.4%) 2 (7.1%)5 (25.0%)
41 (3.0%)3 (20.0%) 0 (0.0%)4 (23.5%) 2 (7.1%)2 (10.0%)
Histology (%) 0.096 0.018 * 0.175
Mixed cell carcinoma3 (9.1%)2 (13.3%) 2 (6.5%)3 (17.6%) 3 (10.7%)2 (10.0%)
Endometrioid28 (84.8%)9 (60.0%) 28 (90.3%)9 (52.9%) 24 (85.7%)13 (65.0%)
Serious carcinoma1 (3.0%)4 (26.7%) 1 (3.2%)4 (23.5%) 1 (3.6%)4 (20.0%)
Clear cell carcinoma1 (3.0%)0 (0.0%) 0 (0.0%)1 (5.9%) 0 (0.0%)1 (5.0%)
ER 1.000 0.974 0.271
05 (15.2%)3 (20.0%) 5 (16.1%)3 (17.6%) 3 (10.7%)5 (25.0%)
1+10 (30.3%)4 (26.7%) 9 (29.0%)5 (29.4%) 8 (28.6%)6 (20.0%)
2+8 (24.2%)3 (20.0%) 8 (25.8%)3 (17.6%) 9 (32.1%)2 (10.0%)
3+10 (30.0%)5 (33.3%) 9 (29.0%)6 (35.3%) 8 (28.6%)7 (35.0%)
PR 0.536 0.334 0.951
03 (9.7%)3 (20.0%) 2 (6.9%)4 (23.5%) 3 (11.5%)3 (15.0%)
1+7 (22.6%)4 (26.7%) 6 (20.7%)5 (29.4%) 6 (23.1%)5 (25.0%)
2+7 (22.6%)4 (26.7%) 8 (27.6%)3 (17.6%) 7 (26.9%)4 (20.0%)
3+14 (45.2%)4 (26.7%) 13 (44.8%)5 (29.4%) 10 (38.5%)8 (40.0%)
Lymphovascular invasion (%) n = 4714 (43.8%)10 (66.7%)0.14311 (36.7%)13 (76.5%)0.015 *15 (53.6%)9 (47.4%)0.676
LN invasion (%) n = 413 (11.1%)5 (35.7%)0.0972 (7.7%)6 (40.0%)0.035 *4 (16.7%)4 (23.5%)0.698
Data are presented as n or mean ± standard deviation. * p-value < 0.05 was considered statistically significant after the test. DM: diabetes mellitus, BMI: body mass index, NLR: neutrophil/lymphocyte ratio, MLR: monocyte/lymphocyte ratio, PLR: platelet/lymphocyte ratio, LN: lymph node.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bing, R.-S.; Tsui, W.L.; Ding, D.-C. The Association between Diabetes Mellitus, High Monocyte/Lymphocyte Ratio, and Survival in Endometrial Cancer: A Retrospective Cohort Study. Diagnostics 2023, 13, 44. https://doi.org/10.3390/diagnostics13010044

AMA Style

Bing R-S, Tsui WL, Ding D-C. The Association between Diabetes Mellitus, High Monocyte/Lymphocyte Ratio, and Survival in Endometrial Cancer: A Retrospective Cohort Study. Diagnostics. 2023; 13(1):44. https://doi.org/10.3390/diagnostics13010044

Chicago/Turabian Style

Bing, Ruo-Shi, Wing Lam Tsui, and Dah-Ching Ding. 2023. "The Association between Diabetes Mellitus, High Monocyte/Lymphocyte Ratio, and Survival in Endometrial Cancer: A Retrospective Cohort Study" Diagnostics 13, no. 1: 44. https://doi.org/10.3390/diagnostics13010044

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop